1. Home
  2. RLAY vs MATH Comparison

RLAY vs MATH Comparison

Compare RLAY & MATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLAY
  • MATH
  • Stock Information
  • Founded
  • RLAY 2015
  • MATH 2015
  • Country
  • RLAY United States
  • MATH Hong Kong
  • Employees
  • RLAY N/A
  • MATH N/A
  • Industry
  • RLAY Biotechnology: Biological Products (No Diagnostic Substances)
  • MATH Finance/Investors Services
  • Sector
  • RLAY Health Care
  • MATH Finance
  • Exchange
  • RLAY Nasdaq
  • MATH Nasdaq
  • Market Cap
  • RLAY 576.1M
  • MATH 60.8M
  • IPO Year
  • RLAY 2020
  • MATH N/A
  • Fundamental
  • Price
  • RLAY $3.60
  • MATH $3.60
  • Analyst Decision
  • RLAY Strong Buy
  • MATH
  • Analyst Count
  • RLAY 11
  • MATH 0
  • Target Price
  • RLAY $18.40
  • MATH N/A
  • AVG Volume (30 Days)
  • RLAY 1.6M
  • MATH 200.0K
  • Earning Date
  • RLAY 08-05-2025
  • MATH 08-26-2025
  • Dividend Yield
  • RLAY N/A
  • MATH N/A
  • EPS Growth
  • RLAY N/A
  • MATH N/A
  • EPS
  • RLAY N/A
  • MATH 0.17
  • Revenue
  • RLAY $7,679,000.00
  • MATH $31,399,049.00
  • Revenue This Year
  • RLAY $17.59
  • MATH N/A
  • Revenue Next Year
  • RLAY N/A
  • MATH N/A
  • P/E Ratio
  • RLAY N/A
  • MATH $21.34
  • Revenue Growth
  • RLAY N/A
  • MATH 291.58
  • 52 Week Low
  • RLAY $1.78
  • MATH $0.80
  • 52 Week High
  • RLAY $10.72
  • MATH $4.17
  • Technical
  • Relative Strength Index (RSI)
  • RLAY 57.25
  • MATH 61.32
  • Support Level
  • RLAY $3.50
  • MATH $3.55
  • Resistance Level
  • RLAY $3.86
  • MATH $3.97
  • Average True Range (ATR)
  • RLAY 0.18
  • MATH 0.32
  • MACD
  • RLAY 0.02
  • MATH 0.03
  • Stochastic Oscillator
  • RLAY 65.79
  • MATH 83.49

About RLAY Relay Therapeutics Inc.

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and derives a majority of its revenue from Hong Kong.

Share on Social Networks: